Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|July 1, 2020
- Pharmaceutical Technology Buyers' Guide 2020
- Volume 2020 Special Issue
Pharmaceutical Technology 2020 Buyers' Guide
Find connections to suppliers of the materials, equipment, and services you need to develop, manufacture, and distribute crucial therapies, treatments, and vaccines in the 2020 Pharmaceutical Technology Buyers' Guide.
Advertisement
Pharmaceutical Technology’s annual Buyers’ Guide is the leading directory of thousands of suppliers of ingredients, materials, and other resources needed for the development and manufacture of solid dose, parenteral, biologic, inhalation, transdermal, and other drug forms.
Use the following links for fast reference to specific technologies and services:
Manufacturing equipment and supplies Cleanroom equipment and supplies Packaging equipment and accessories Laboratory equipment and supplies Information technologies Outsourcing services .
In addition, read about trends and innovations in the guide’s
For more online resources, visit the
Advertisement
Related to this article
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
Advertisement
Advertisement